Rotigotine Luye
(Single Day Rotigotine Transdermal Patch)
Therapeutic indications:
Rotigotine is indicated for the treatment of:
Restless Legs Syndrome (RLS): 1, 2 and 3 mg/24h For symptomatic treatment of moderate to severe idiopathic RLS in adults.
Parkinson’s Disease: 2, 4, 6 and 8 mg/24h As monotherapy in early-stage idiopathic Parkinson’s disease or in combination with levodopa for later stages when levodopa’s efficacy diminishes or becomes unstable (“On-off” fluctuations).
View the Prescribing Information
Adverse events should be reported
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Luye Pharma Ltd at safety@luyepharma.co.uk.
Download the SmPC
This link will take you to the electronic medicines compendium (emc) website.
This is a Prescription only Medication and is only available as a pharmacy order.
Technical information
| Active Ingredients: | Rotigotine |
| Therapeutic area: | Neurology |
| Pharmaceutical Form: | Transdermal Patch |
Strengths, Pack size and Information
| Description | Strength | Pack Size | PIP Code |
|---|---|---|---|
| Rotigotine Luye | 1mg | 28 patches | 540-3373 |
| Rotigotine Luye | 2mg | 28 patches | 540-3324 |
| Rotigotine Luye | 3mg | 28 patches | 540-3340 |
| Rotigotine Luye | 4mg | 28 patches | 540-3332 |
| Rotigotine Luye | 6mg | 28 patches | 540-3357 |
| Rotigotine Luye | 8mg | 28 patches | 540-3365 |